Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: Therapeutic implications for hepatitis C

Journal of Hepatology

Volumn 50, Issue 1, 2009, Pages 140-149

  Wedemeyer, Inga ^a   Bechmann, Lars P ^b   Odenthal, Margarethe ^a   Jochum, Christoph ^b   Marquitan, Guido ^b   Drebber, Uta ^a   Gerken, Guido ^b   Gieseler, Robert K ^b   Dienes, Hans P ^a   Canbay, Ali ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Adiponectin; AdipoR1; AdipoR2; Apoptosis; CD95 Fas; Free fatty acids; HCV; HepG2 cells; M30; Steatosis

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; FAS ANTIGEN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENOTYPE; HEPATITIS C; HEPATOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STEATOSIS; UPREGULATION;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; APOPTOSIS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATOBLASTOMA; HEPATOCYTES; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RECEPTORS, ADIPONECTIN; UP-REGULATION;

EID: 56949108414     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.08.023     Document Type: Article

References (47)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
2. Chang M.L., Yeh C.T., Chen J.C., Huang C.C., Lin S.M., Sheen I.S., et al. Altered expression patterns of lipid metabolism genes in an animal model of HCV core-related, nonobese, modest hepatic steatosis. BMC Genomics 9 (2008) 109
3. Okuda M., Li K., Beard M.R., Showalter L.A., Scholle F., Lemon S.M., et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122 (2002) 366-375
4. Canbay A., Friedman S., and Gores G.J. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39 (2004) 273-278
5. Bantel H., and Schulze-Osthoff K. Apoptosis in hepatitis C virus infection. Cell Death Differ 10 (2003) S48-S58
6. Watanabe-Fukunaga R., Brannan C.I., Copeland N.G., Jenkins N.A., and Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356 (1992) 314-317
7. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., et al. Lethal effect of the anti-Fas antibody in mice. Nature 364 (1993) 806-809
8. Hiramatsu N., Hayashi N., Katayama K., Mochizuki K., Kawanishi Y., Kasahara A., et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 19 (1994) 1354-1359
9. Mita E., Hayashi N., Iio S., Takehara T., Hijioka T., Kasahara A., et al. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun 204 (1994) 468-474
10. Pianko S., Patella S., Ostapowicz G., Desmond P., and Sievert W. Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection. J Viral Hepat 8 (2001) 406-413
11. Marchesini G., Marzocchi R., Agostini F., and Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 16 (2005) 421-427
12. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., and Cooper G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112 (2003) 91-100
13. Kamada Y., Tamura S., Kiso S., Matsumoto H., Saji Y., Yoshida Y., et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125 (2003) 1796-1807
14. Masaki T., Chiba S., Tatsukawa H., Yasuda T., Noguchi H., Seike M., et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 40 (2004) 177-184
15. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2003) 762-769
16. Vuppalanchi R., Marri S., Kolwankar D., Considine R.V., and Chalasani N. Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J Clin Gastroenterol 39 (2005) 237-242
17. Petit J.M., Minello A., Jooste V., Bour J.B., Galland F., Duvillard L., et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab 90 (2005) 2240-2243
18. Durante-Mangoni E., Zampino R., Marrone A., Tripodi M.F., Rinaldi L., Restivo L., et al. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther 24 (2006) 1349-1357
19. Liu C.J., Chen P.J., Jeng Y.M., Huang W.L., Yang W.S., Lai M.Y., et al. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol 43 (2005) 235-242
20. Howard C. Hepatitis C virus: clades and properties. J Gastroenterol Hepatol 17 (2002) S468-S470
21. Jonsson J.R., Moschen A.R., Hickman I.J., Richardson M.M., Kaser S., Clouston A.D., et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 43 (2005) 929-936
22. Mafra D., Guebre-Egziabher F., and Fouque D. Body mass index, muscle and fat in chronic kidney disease: questions about survival. Nephrol Dial Transplant 23 (2008) 2461-2466
23. Mulder C., Schouten J.A., and Popp-Snijders C. Determination of free fatty acids: a comparative study of the enzymatic versus the gas chromatographic and the colorimetric method. J Clin Chem Clin Biochem 21 (1983) 823-827
24. Xu A., Chan K.W., Hoo R.L., Wang Y., Tan K.C., Zhang J., et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 280 (2005) 18073-18080
25. Bantel H., Lugering A., Heidemann J., Volkmann X., Poremba C., Strassburg C.P., et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 40 (2004) 1078-1087
26. Bechmann L.P., Marquitan G., Jochum C., Saner F., Gerken G., and Canbay A. Apoptosis versus necrosis rate as a predictor in acute liver failure following acetaminophen intoxication compared with acute-on-chronic liver failure. Liver Int 28 (2008) 713-716
27. Desmet V.J., Gerber M., Hoofnagle J.H., Manns M., and Scheuer P.J. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19 (1994) 1513-1520
28. Dries V., von Both I., Muller M., Gerken G., Schirmacher P., Odenthal M., et al. Detection of hepatitis C virus in paraffin-embedded liver biopsies of patients negative for viral RNA in serum. Hepatology 29 (1999) 223-229
29. Wieckowska A., Zein N.N., Yerian L.M., Lopez A.R., McCullough A.J., and Feldstein A.E. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44 (2006) 27-33
30. Bulcao C., Ferreira S.R., Giuffrida F.M., and Ribeiro-Filho F.F. The new adipose tissue and adipocytokines. Curr Diabetes Rev 2 (2006) 19-28
31. Matarese G., Mantzoros C., and La Cava A. Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis. Curr Pharm Des 13 (2007) 3676-3680
32. Savino F., Petrucci E., and Nanni G.E. Adiponectin: an intriguing hormone for paediatricians. Acta Paediatr 97 (2008) 701-705
33. Rakatzi I., Seipke G., and Eckel J. [LysB3, GluB29] insulin: a novel insulin analog with enhanced beta-cell protective action. Biochem Biophys Res Commun 310 (2003) 852-859
34. Neumeier M., Hellerbrand C., Gabele E., Buettner R., Bollheimer C., Weigert J., et al. Adiponectin and its receptors in rodent models of fatty liver disease and liver cirrhosis. World J Gastroenterol 12 (2006) 5490-5494
35. Hui J.M., Hodge A., Farrell G.C., Kench J.G., Kriketos A., and George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 40 (2004) 46-54
36. Musso G., Gambino R., Biroli G., Carello M., Faga E., Pacini G., et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 100 (2005) 2438-2446
37. Bugianesi E., Pagotto U., Manini R., Vanni E., Gastaldelli A., de Iasio R., et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90 (2005) 3498-3504
38. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
39. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
40. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 (2001) 1930-1935
41. Goldstein B.J., and Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89 (2004) 2563-2568
42. Loguercio C., De Simone T., D'Auria M.V., de Sio I., Federico A., Tuccillo C., et al. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Dig Liver Dis 36 (2004) 398-405
43. Locksley R.M., Killeen N., and Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104 (2001) 487-501
44. Galle P.R., Hofmann W.J., Walczak H., Schaller H., Otto G., Stremmel W., et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 182 (1995) 1223-1230
45. Galle P.R., and Krammer P.H. CD95-induced apoptosis in human liver disease. Semin Liver Dis 18 (1998) 141-151
46. Lauber K., Bohn E., Krober S.M., Xiao Y.J., Blumenthal S.G., Lindemann R.K., et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 113 (2003) 717-730
47. Canbay A., Guicciardi M.E., Higuchi H., Feldstein A., Bronk S.F., Rydzewski R., et al. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest 112 (2003) 152-159